Key result
ATTR cardiac amyloidosis is linked to clinical anxiety or depression in ~49% of outpatients.
Why the study?
No study had analyzed the prevalence of anxiety and depression symptoms and their clinical and sociodemographic correlates in patients with ATTR cardiac amyloidosis.
Cross-Sectional (n=142)
No
Supports mental health screening in ATTR cardiac amyloidosis care; hypothesis-generating for intervention trials.
Patients with ATTR cardiac amyloidosis (ATTR-CA) face rare disease that could negatively influence psychological well-being with consequences on the course of the disease and quality of life. However, to date, no study analyzed the prevalence of anxiety and depression in patients with ATTR-CA and which clinical and sociodemographic characteristics are linked with these psychopathological conditions. A total of 109 consecutive patients (83% males) aged 62-90 years with ATTR-CA were recruited. In order to better understand the prevalence of anxiety and depression in ATTR-CA, a control group composed by 33 individuals equaling gender, education, and age were recruited. The level of anxiety and depression was measured using the Italian version of the Hospital Anxiety and Depression Scale (HADS). Sociodemographic and clinic characteristics were registered. Almost half of patients (49%) reported a clinical level of depression or anxiety, or both. ATTR-CA patients reported higher levels of anxiety and depression than control group. Results showed that older patients with ATTR-CA, especially females, with more advanced disease could be more at risk to develop an anxious disorder. Furthermore, being a woman, and presenting with a greater severity of symptoms, would appear to be a risk factor for developing a depressive disorder. Overall, these results highlighted the high presence of anxiety and depression in ATTR-CA patients, suggesting to physicians to pay attention to the psychological well-being of ATTR-CA patients. In fact, a psychological support for patients with high level of psychopathological disease could reduce disease burden and improve quality of life in ATTR-CA population.
No takes yet. Share an insight, caveat, or question.
Smorti et al. (2023) conducted a cross-sectional in ATTR cardiac amyloidosis (n=142). ATTR cardiac amyloidosis vs. Individuals without cardiac pathology was evaluated on Clinical level of depression or anxiety, or both (HADS score ≥ 8). Almost half (48.6%) of outpatients with ATTR cardiac amyloidosis reported clinical levels of anxiety or depression, which were higher than in the matched control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: